Oncology

with Horizon

At Synapse Laboratory, our Oncology services are dedicated to providing advanced diagnostic and treatment solutions for solid tumors. Through cutting-edge DNA and RNA panel testing, we offer precise and personalized cancer care, helping healthcare providers deliver the best possible outcomes for their patients.

Our services are designed to enhance diagnostic accuracy, optimize therapeutic strategies, and improve patient outcomes.

Solid Tumor Profiling

Our solid tumor profiling services use comprehensive DNA and RNA panels to identify specific genetic mutations and expression profiles in tumors. This allows for personalized treatment plans that target the unique characteristics of each patient’s cancer.

  • Oncology 179 and 192
    This service includes a DNA panel covering 42 genes and an RNA panel with 137 gene fusions. Genomic DNA and RNA are extracted from the patient’s FFPE sample, and the enriched libraries are sequenced using the Illumina platform, providing detailed insights for tailored cancer treatment.
  • Oncology 1000
    A comprehensive genomic profiling service for solid tumors, this test covers a wide range of genes using tissue or blood specimens. It’s ideal for managing complex, advanced, or refractory cancer cases, providing deep insights to guide treatment decisions

Lung Cancer Testing

Lung cancer is one of the most common and serious types of cancer. Our specialized testing services help in the precise diagnosis and management of non-small cell lung cancer (NSCLC).

  • Lung PCR
    This real-time PCR panel targets 167 hotspot alterations in 11 driver genes specifically associated with NSCLC. It assists healthcare providers in determining the most effective treatment options based on the patient’s molecular profile.

Immunohistochemistry (IHC) Testing

Immunohistochemistry testing is critical for understanding the protein expression within tumors, guiding immunotherapy treatments.

  • PD-L1 Immunohistochemistry (IHC) Test
    This test evaluates the expression of PD-L1, a protein that can be targeted by specific immunotherapies like KEYTRUDA and OPDIVO. By understanding the level of PD-L1 expression, healthcare providers can make informed decisions about using these therapies to boost the immune response and reduce tumor growth.

Want to know more about Horizon Oncology tests?

To learn more about our innovative solutions and how we deliver precise, reliable results, please reach out to us

Unit 201-205, Block D, 17, Kelana Square,
Jalan SS 7/26, SS7, 47301
Petaling Jaya, Selangor,
Malaysia

Call us E-mail

Our Brands

Deparments

  • Molecular Genetics
  • Molecular Diagnostics
  • Biochemical Genetics
  • Health Informatics